Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaRecent progress in pancreatic cancerEmerging concepts in pancreatic cancer medicine: targeting the tumor stromaPancreatic Cancer from Molecular Pathways to Treatment OpinionPancreatic cancer from bench to bedside: molecular pathways and treatment optionsHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Systemic Chemotherapy in Advanced Pancreatic CancerMolecular therapeutics in pancreas cancerIs metastatic pancreatic cancer an untargetable malignancy?From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cellsNeoadjuvant radiotherapeutic strategies in pancreatic cancerCurrent therapeutic strategies for advanced pancreatic cancer: A review for cliniciansState of the art biological therapies in pancreatic cancerMolecular targets for the treatment of pancreatic cancer: Clinical and experimental studiesEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsNovel agents for advanced pancreatic cancerPerspectives in the treatment of pancreatic adenocarcinomaNeoadjuvant therapy for localized pancreatic cancer: guiding principlesPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesCurrent status and progress of pancreatic cancer in ChinaAdvances in systemic therapy for advanced pancreatobiliary malignanciesThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewMolecular landscape of pancreatic cancer: implications for current clinical trialsImaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted NanovesiclesSystemic treatment for inoperable pancreatic adenocarcinoma: review and updateSpecificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerCXCR2: a target for pancreatic cancer treatment?Systemic therapies for pancreatic cancer--the role of pharmacogeneticsThe pancreas cancer microenvironmentFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerMetastatic pancreatic cancer: Is there a light at the end of the tunnel?Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implicationsInhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeuticsFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentNovel analogue of colchicine induces selective pro-death autophagy and necrosis in human cancer cellsTumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab TherapyA genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineGemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
P2860
Q21129230-60B067EC-AFB2-47FF-8167-FB57EAC0C387Q24626346-012F015C-72CC-415C-9B9A-394408E215BAQ24627664-9C98EAB3-B614-453E-9947-03909BE2E0D1Q26743482-990E243E-D70D-4FFA-88EB-059CDAFEDF51Q26747524-811212F7-0766-47EF-A4D9-5C513E7EB88AQ26747695-E8337F83-56E8-4825-BDCF-4118DC5768A8Q26750440-23DA1A0C-F880-4A40-857B-8D22806650EAQ26751709-07218CFE-A7E0-4DF5-B988-49C14E688850Q26753849-96E6AE74-17FE-4B35-B0A5-3FB9AE248BC9Q26765123-37589A77-915B-4A67-9FB9-D3670BE40D0EQ26766065-A52538BB-6A93-4DED-A632-2B5F797B3C24Q26766686-103017EC-B435-4DC9-A905-6BBBAD0B4BFBQ26767041-91391B3C-0500-4F01-99A9-A5800C3DA7F8Q26769941-1EC203A1-9EE3-4403-95CC-6E7536016C2AQ26774636-AC00C021-D0B0-4EFC-8018-C079454C0F07Q26786618-276DC7EE-346B-4283-A908-1801EF5AF4EDQ26787087-0E51595B-FD23-403D-B639-C28AC2FF782BQ26797248-1E677DA2-E613-449D-98D6-E4AE4FE272AEQ26799428-57738E19-618C-4655-BF01-B76C3E49C7BEQ26799714-2F5EAC48-D2D1-4E83-A1A9-A2A72F1E0692Q26799739-A583EA1E-0B01-4B39-A816-BBC7CBD36905Q26822703-839BC56E-AD9E-463D-90E7-B2850B682D96Q26824086-4AFE55E4-9A7C-4364-A631-9B94CC587641Q26824528-8627AD77-9B31-447A-A2F5-CBD7185D3A1DQ26828959-B09E3FB2-8B16-4981-AF7F-7360950FA8D5Q26830913-D385420B-7CEC-4D48-A049-EFC9B06C87C1Q26853171-079AC98D-627A-4F8A-88E2-9C3A1F3D1F33Q27021588-DF3F37C7-DF16-4CF1-8E27-CC01C6F5FA4BQ27021716-6E3ECC54-419C-44E3-A231-893DBFFACCD7Q27026705-4EA40AC0-9585-41B7-A110-0322C0094DBFQ28075540-5A3E3A02-145F-4AAD-9591-03A14B0A4C30Q28082919-071983B0-56C3-4F29-903D-8225C26D89D9Q28269990-E3A87C88-4AED-4826-BE47-4A091C4753D5Q28487715-9CE0601A-8E17-4DAA-AC32-535A106AA205Q28533949-D6656534-A6C8-4965-B65B-FB012E7C30A6Q28539109-BE9364BB-433E-4E7C-B3E9-CE01C486AEC0Q28550733-A4781A16-A46A-4139-B1D2-798A48FB836DQ28943270-D0583077-CC51-4463-B262-3B78F478A9C5Q29616728-D7AC4332-AC23-4AB5-9A4F-7C4DAB15766DQ30235450-353855D9-9532-440C-86F8-58EB7FE89E70
P2860
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Gemcitabine plus bevacizumab c ...... eukemia Group B (CALGB 80303).
@ast
Gemcitabine plus bevacizumab c ...... eukemia Group B (CALGB 80303).
@en
Gemcitabine plus bevacizumab c ...... he Cancer and Leukemia Group B
@nl
type
label
Gemcitabine plus bevacizumab c ...... eukemia Group B (CALGB 80303).
@ast
Gemcitabine plus bevacizumab c ...... eukemia Group B (CALGB 80303).
@en
Gemcitabine plus bevacizumab c ...... he Cancer and Leukemia Group B
@nl
prefLabel
Gemcitabine plus bevacizumab c ...... eukemia Group B (CALGB 80303).
@ast
Gemcitabine plus bevacizumab c ...... eukemia Group B (CALGB 80303).
@en
Gemcitabine plus bevacizumab c ...... he Cancer and Leukemia Group B
@nl
P2093
P2860
P921
P356
P1476
Gemcitabine plus bevacizumab c ...... Leukemia Group B (CALGB 80303)
@en
P2093
Deborah Schrag
Donna Hollis
Donna Niedzwiecki
Federico Innocenti
Hedy Lee Kindler
Herbert Hurwitz
Joel Picus
Mary Frances Mulcahy
Pankaj Bhargava
Richard L Schilsky
P2860
P304
P356
10.1200/JCO.2010.28.1386
P407
P577
2010-07-06T00:00:00Z